United States - English - NLM (National Library of Medicine)

united natural foods, inc. dba unfi - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 1 g in 100 g - anti-itch

United States - English - NLM (National Library of Medicine)

bobbi brown professional cosmetics inc. - octinoxate 7.0% octisalate 4.5% titanium dioxide 4.2% - sunscreen helps prevent sunburn

United States - English - NLM (National Library of Medicine)

makeup art cosmetics - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - octinoxate 0.05425 g in 100 ml - helps prevent sunburn apply directly to face. blend with finger, sponge or appropriate foundation brush.

United States - English - NLM (National Library of Medicine)

bobbi brown professional cosmetics inc. - octinoxate 3.9%, titanium dioxide 6.1%, zinc oxide 3.8% - sunscreen helps prevent sunburn

United States - English - NLM (National Library of Medicine)

likewise incorporated - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - octinoxate 75 mg in 1 ml - uses  - helps prevent sunburn  - higher spf provides more protection  - retains spf after 40 minutes of activity in water or vigorous sweating. stop use and ask a doctor if rash or irritation develops and lasts. - helps prevent sunburn - higher spf provides more protection - retains spf after 40 minutes of activity in water or vigorous sweating.

United States - English - NLM (National Library of Medicine)

schwabe north america, inc - guaifenesin (unii: 495w7451vq) (guaifenesin - unii:495w7451vq) - guaifenesin 200 mg

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 g - desonide cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

likewise incorporated - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - octinoxate 75 mg in 1 ml - uses  - helps prevent sunburn  - higher spf provides more protection  - retains spf after 40 minutes of activity in water or vigorous sweating. - helps prevent sunburn - higher spf provides more protection - retains spf after 40 minutes of activity in water or vigorous sweating. stop use and ask a doctor if rash or irritation develops and lasts.

United States - English - NLM (National Library of Medicine)

likewise incorporated - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - octinoxate 75 mg in 1 ml - uses  - helps prevent sunburn  - higher spf provides more protection  - retains spf after 40 minutes of activity in water or vigorous sweating. - helps prevent sunburn - higher spf provides more protection - retains spf after 40 minutes of activity in water or vigorous sweating. stop use and ask a doctor if rash or irritation develops and lasts.

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 g - desonide cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide cream, 0.5% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. safety and effectiveness in pediatric patients have not been established. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of hpa axis suppression and cushing’s syndrome when they are treated with topical corticosteroids. they are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. hpa axis suppression, cushing’s syndrome, linear growth retardation